Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Accuray Incorporated (ARAY : NSDQ)
 
 • Company Description   
Accuray Inc. designs, develops & sells radiosurgery and radiation therapy systems for treatment of tumors in the body. The company's product suite includes the CyberKnife Systems and the TomoTherapy Systems. It primarily generates revenues by selling the CyberKnife & TomoTherapy Systems and providing ongoing services and upgrades to customers following installation of the CyberKnife System. Product revenues include sales of linacs for other uses. It also offers optional hardware and software, technical enhancements and upgrades to the CyberKnife & TomoTherapy System. The CyberKnife Systems include: the CyberKnife G4, CyberKnife VSI System and the new CyberKnife M6 Series System. TomoTherapy Systems include the Hi-Art System, delivering CT-guided, helical intensity modulated radiation therapy; the TomoHD System and the Tomo H Series Systems.

Number of Employees: 995

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.31 Daily Weekly Monthly
20 Day Moving Average: 892,977 shares
Shares Outstanding: 92.80 (millions)
Market Capitalization: $214.37 (millions)
Beta: 1.92
52 Week High: $5.93
52 Week Low: $2.08
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -29.36% -22.89%
12 Week -36.19% -31.03%
Year To Date -51.57% -42.64%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1310 CHESAPEAKE TERRACE
-
SUNNYVALE,CA 94089
USA
ph: 408-716-4600
fax: 408-716-4601
aman.patel@westwicke.com http://www.accuray.com
 
 • General Corporate Information   
Officers
Joshua H. Levine - Chief Executive Officer and Director
Joseph E. Whitters - Chairperson of the Board and Director
Shig Hamamatsu - Chief Financial Officer
Elizabeth Davila - Director
Byron C. Scott - Director

Peer Information
Accuray Incorporated (ABMD)
Accuray Incorporated (DMDS)
Accuray Incorporated (CPWY.)
Accuray Incorporated (EQUR)
Accuray Incorporated (ECIA)
Accuray Incorporated (FMS)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 004397105
SIC: 3841
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 92.80
Most Recent Split Date: (:1)
Beta: 1.92
Market Capitalization: $214.37 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.12 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.15
Price/Cash Flow: 19.01
Price / Sales: 0.50
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -6.23%
vs. Previous Quarter: -17.29%
ROE
03/31/22 - -5.68
12/31/21 - -3.98
09/30/21 - 3.19
ROA
03/31/22 - -0.65
12/31/21 - -0.51
09/30/21 - 0.45
Current Ratio
03/31/22 - 1.72
12/31/21 - 1.72
09/30/21 - 1.86
Quick Ratio
03/31/22 - 1.04
12/31/21 - 1.11
09/30/21 - 1.19
Operating Margin
03/31/22 - -0.72
12/31/21 - -0.56
09/30/21 - 0.52
Net Margin
03/31/22 - -3.01
12/31/21 - -2.82
09/30/21 - -1.85
Pre-Tax Margin
03/31/22 - -2.62
12/31/21 - -2.36
09/30/21 - -1.41
Book Value
03/31/22 - 0.56
12/31/21 - 0.55
09/30/21 - 0.50
Inventory Turnover
03/31/22 - 2.10
12/31/21 - 2.12
09/30/21 - 1.93
Debt-to-Equity
03/31/22 - 3.36
12/31/21 - 3.42
09/30/21 - 4.24
Debt-to-Capital
03/31/22 - 77.04
12/31/21 - 77.39
09/30/21 - 80.92
 

Powered by Zacks Investment Research ©